Immepip dihydrobromide is a potent and specific H3 agonist[1]. Immepip dihydrobromide can readily cross the blood-brain barrier and drastically decrease brain neuronal histamine release in the rat [2]. Immepip dihydrobromide has been widely used to regulate the levels of GABA and glutamate and to alleviate the movement disorders in animals[3].
In vitro, Immepip dihydrobromide treatment (100nM) for 15min prevented the inhibitory effect of H3 receptor activation on forskolin-induced [3H]-cAMP accumulation in [3H]-adenine-labeled rat striatal slices[4]. The treatment with Immepip dihydrobromide (1µM) for 1 hour significantly inhibited the secretion of glucagon by αTC1.6 cells and suppressed the increase in intracellular Ca2+ concentration[5].
In vivo, Immepip dihydrobromide treatment via intravenous injection at a dose of 10µg/kg/min for 10 minutes significantly inhibited the tachycardia response induced by the sympathetic nerve in rats[6]. Injection of Immepip dihydrobromide (10µl; 30μM) through the third cerebral ventricle (i3v) reduced the locomotor behavior of rats within 90 minutes and induced feeding behaviors[7].
References:
[1] Lamberty Y, Margineanu D G, Dassesse D, et al. H3 agonist immepip markedly reduces cortical histamine release, but only weakly promotes sleep in the rat[J]. Pharmacological research, 2003, 48(2): 193-198.
[2] Jansen F P, Mochizuki T, Yamamoto Y, et al. In vivo modulation of rat hypothalamic histamine release by the histamine H3 receptor ligands, immepip and clobenpropit. Effects of intrahypothalamic and peripheral application[J]. European journal of pharmacology, 1998, 362(2-3): 149-155.
[3] Avila-Luna A, Ríos C, Gálvez-Rosas A, et al. Chronic administration of the histamine H3 receptor agonist immepip decreases l-Dopa-induced dyskinesias in 6-hydroxydopamine-lesioned rats[J]. Psychopharmacology, 2019, 236(6): 1937-1948.
[4] Garduño‐Torres B, Arias‐Montaño J A. Homologous down‐regulation of histamine H3 receptors in rat striatal slices[J]. Synapse, 2006, 60(2): 165-171.
[5] Nakamura T, Yoshikawa T, Naganuma F, et al. Role of histamine H3 receptor in glucagon-secreting αTC1. 6 cells[J]. FEBS Open bio, 2015, 5: 36-41.
[6] Pinacho-García M, Marichal-Cancino B A, Villalón C M. Further evidence for the role of histamine H3, but not H1, H2 or H4, receptors in immepip-induced inhibition of the rat cardioaccelerator sympathetic outflow[J]. European Journal of Pharmacology, 2016, 773: 85-92.
[7] Chiba S, Itateyama E, Sakata T, et al. Acute central administration of immepip, a histamine H3 receptor agonist, suppresses hypothalamic histamine release and elicits feeding behavior in rats[J]. Brain research bulletin, 2009, 79(1): 37-40.
Immepip dihydrobromide是一种强效且特异性的H3受体激动剂[1]。Immepip dihydrobromide易于通过血脑屏障,并能显著降低大鼠脑内神经元组胺的释放[2]。Immepip dihydrobromide已被广泛用于调节GABA 和谷氨酸水平,并缓解动物的运动障碍[3]。
在体外,使用100nM的Immepip dihydrobromide处理15分钟,可阻止H3受体激活对[³H]-腺嘌呤标记的大鼠纹状体切片中毛喉素诱导的[3H]-cAMP积累所产生的抑制作用[4]。使用1µM的Immepip dihydrobromide处理αTC1.6细胞1小时,显著抑制了胰高血糖素的分泌,并抑制了细胞内Ca2+浓度的升高[5]。
在体内,静脉注射10µg/kg/min剂量的Immepip dihydrobromide,持续10分钟,显著抑制了交感神经诱导的大鼠心动过速反应[6]。通过第三脑室(i3v)注射10µl的30μM的Immepip dihydrobromide,可在90分钟内减少大鼠的运动行为并诱导摄食行为[7]。
















